Health Trials

Recurrent Or Metastatic Solid Tumors

3

Review clinical trials related to Recurrent Or Metastatic Solid Tumors. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

A Study of Subcutaneous Trastuzumab Deruxtecan in Participants With Metastatic Solid Tumors

This is a dose escalation, and dose expansion study of T-DXd plus hyaluronidase administered subcutaneously, to assess the safety, tolerability, PK and efficacy of SC T-DXd plus hyaluronidase in participants with metastatic solid tumors.

Participants needed: 76
Trial details
Phase: Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: Daiichi SankyoUpdated: Mar 20, 2026Locations: 26
Eligibility criteria

Sign and date the ICF, prior to the start of any trial- specific qualification p... [+13]

At least 1 year has elapsed since last dose of exatecan derivative ADC. [+8]

Read more
Status: Recruiting

A Study To Evaluate The Efficacy And Safety Of Ifinatamab Deruxtecan (I-DXd) In Subjects With Recurrent Or Metastatic Solid Tumors (IDeate-PanTumor02)

This study is designed to assess the efficacy and safety of ifinatamab deruxtecan (I-DXD) in the following tumor types: endometrial cancer (EC); head and neck squamous cell carcinoma (HNSCC); pancreatic ductal adenocarcinoma (PDAC); colorectal cancer (CRC); hepatocellular carcinoma (HCC); adenocarcinoma of esophagus, gastroesophageal junction, and stomach (Ad-Eso/GEJ/gastric); urothelial carcinoma (UC); ovarian cancer (OVC); cervical cancer (CC); biliary tract cancer (BTC); human epidermal growth factor 2 (HER2)-low breast cancer (BC); HER2 immunohistochemistry (IHC) 0 BC; and cutaneous melanoma.

Participants needed: 520
Trial details
Phase: Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Daiichi SankyoUpdated: Feb 12, 2026Locations: 119
Eligibility criteria

Participant must have at least 1 lesion, not previously irradiated, amenable to... [+51]

Read more
Status: Not yet recruiting

An Exploratory Study of A-337 in the Management of Malignant Solid Dose Escalation and Expansion Phases

Title: An Exploratory Study of A-337 in the Management of Malignant Solid Dose Escalation and Expansion Phases

Participants needed: 94
Trial details
Phase: Phase 1Age: 18-75Biological sex: AllType: InterventionalSponsor: ITabMed Co., Ltd.Updated: Oct 23, 2023
Eligibility criteria

18-75 years, all genders [+11]

Past or present malignant tumor diagnosed in the past 3 years and/or required tr... [+26]

Read more